Use of recombinant factor VIIa (NovoSeven®) in patients with Glanzmann thrombasthenia
MC Poon, R d'Oiron, I Hann, C Négrier… - Seminars in …, 2001 - Elsevier
Recombinant factor VIIa (rFVIIa; NovoSeven®, Novo Nordisk, Bagsvaerd, Denmark)
appears effective and relatively safe for the treatment of bleeding and for surgical
prophylaxis in patients with Glanzmann thrombasthenia as reported to the International
Registry on rFVIIa and Congenital Platelet Disorders. One of the shortcomings of the
Registry data is the heterogeneity of treatment protocol, including dosage, number of doses
used, duration of treatment before declaration of failure, and mode of rFVIIa administration …
appears effective and relatively safe for the treatment of bleeding and for surgical
prophylaxis in patients with Glanzmann thrombasthenia as reported to the International
Registry on rFVIIa and Congenital Platelet Disorders. One of the shortcomings of the
Registry data is the heterogeneity of treatment protocol, including dosage, number of doses
used, duration of treatment before declaration of failure, and mode of rFVIIa administration …
